Enovis™ Announces Leadership Change to International Surgical Business
17 Januar 2025 - 12:00PM
Enovis™, a global medical technology innovator headquartered in the
United States, announced recently that Davide Visentin will succeed
Dr. Benjamin Reinmann as President of Enovis International
Surgical, effective March 1, 2025.
Visentin is a successful MedTech executive who comes to Enovis
with more than 20 years of healthcare experience. Most recently, he
was the Vice President and General Manager of the Integrated
Diagnostic Solutions Business Unit for BD, where he managed more
than 700 employees across 50 countries and gained market share in a
very competitive market. Prior to BD, Visentin served as Vice
President and General Manager of Europe for Stryker’s Joint
Replacement and Robotic Division, and Vice President, EMEA, for
Johnson & Johnson Depuy Synthes.
“Under Benjamin Reinmann’s leadership, Enovis has created a
world-class International Surgical Business. We sincerely thank
Benjamin for his numerous contributions to the growth and success
of both Enovis and Mathys, and especially throughout the critical
integration of legacy companies Mathys and LimaCorporate,” said
Louie Vogt, Group President of Enovis’ Reconstructive Business
Group. “We are very excited to welcome Davide to Enovis. He is a
dynamic leader with a strong track record of successfully growing
businesses, a true passion for orthopedics, and the experience and
playbook to take our business to the next level.”
Visentin has a degree in Computer Science from the University of
Milan. He will primarily spend his time in Villanova, Italy, and
Bettlach, Switzerland.
“We continue to make great progress with building and growing
our International Surgical Business into a global orthopedics
leader that is thriving because of our team’s commitment to
excellence and to going above and beyond every day to create better
together,” added Vogt. “The momentum we created in 2024 puts us in
a strong position to advance our strategic goals, continue gaining
market share and drive growth through innovation, all with the
ultimate goal of improving patient outcomes.”
About EnovisEnovis™ (NYSE: ENOV) is a global
medical technology innovator dedicated to improving lives by
developing clinically differentiated solutions that enhance patient
outcomes and restore motion for life. We partner with the brightest
minds in health to advance care that is smarter, personalized, and
more effective, while improving operational efficiency for surgeons
and clinicians around the world. Enovis solutions impact the
well-being of millions of patients wherever they are on their
pathway to health. Learn more about Enovis at www.enovis.com.
Media Contact
Lee GriffinVice President, Global Marketing Communications &
Digital, Enovis+1 (469) 794-9760Lee.Griffin@enovis.com
Enovis (NYSE:ENOV)
Historical Stock Chart
Von Dez 2024 bis Jan 2025
Enovis (NYSE:ENOV)
Historical Stock Chart
Von Jan 2024 bis Jan 2025